Linden Thomas Advisory Services LLC Has $1.66 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Linden Thomas Advisory Services LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 2.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 13,376 shares of the medical device company’s stock after buying an additional 330 shares during the period. Linden Thomas Advisory Services LLC’s holdings in DexCom were worth $1,660,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Sands Capital Management LLC increased its holdings in shares of DexCom by 4.3% during the third quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after acquiring an additional 557,543 shares in the last quarter. Blair William & Co. IL grew its stake in DexCom by 1.7% in the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock valued at $420,517,000 after purchasing an additional 73,654 shares during the period. Northern Trust Corp lifted its position in shares of DexCom by 2.4% during the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock valued at $363,545,000 after buying an additional 91,249 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of DexCom by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company’s stock valued at $201,618,000 after buying an additional 28,621 shares during the last quarter. Finally, Winslow Capital Management LLC purchased a new position in shares of DexCom during the 3rd quarter valued at $173,120,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Up 1.8 %

Shares of DXCM traded up $2.36 on Wednesday, reaching $136.36. The stock had a trading volume of 1,193,450 shares, compared to its average volume of 2,935,815. The firm has a market capitalization of $52.57 billion, a price-to-earnings ratio of 102.29, a price-to-earnings-growth ratio of 2.26 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The company has a 50-day simple moving average of $130.15 and a 200-day simple moving average of $117.74. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm’s quarterly revenue was up 26.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.34 earnings per share. Sell-side analysts predict that DexCom, Inc. will post 1.76 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DXCM. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada began coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $141.40.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.